Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clopidogrel versus placebo in neonates and infants with cyanotic congenital heart disease after systemic-to-pulmonary artery shunt
2006-000946-38Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cardiovascular Malformation (CVM) comparing Clopidogrel with Placebo (2 arms). Primary endpoints: Primary composite efficacy endpoint and All-cause mortality and shunt-related morbidity. Started Sep 2006; status: completed.
02
Drugs
clopidogrel
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on 2006-000946-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000946-38.